Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- obesity/erectile dysfunction -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (109)	6/16/2003 2:33:55 AM
From: russet	Respond to of 435

Yah,...as you know we have solved 99% of all problems of genetically screwed up mice and rats,...oncology, physiology, psychology even,....now if they would only return the favor!! (ggggggggggg) Do Swedish women solve all our problems??? Can German women substitute? Can weed really substitute for both :-))

To: scaram(o)uche who wrote (109)	7/30/2003 11:15:32 AM
From: keokalani'nui	Read Replies (1) \| Respond to of 435

Phytopharm Says Pfizer To Discontinue P57 Development Wednesday July 30, 10:36 am ET Edited Press Release LONDON -(Dow Jones)- Phytopharm announced Wednesday that it has received notice from Pfizer that it will discontinue clinical development of P57 for the treatment of obesity and return the rights to the company. P57 is a novel appetite suppressant that has been shown to reduce caloric intake in overweight subjects, as announced by Phytopharm in December 2001. In a changing environment for discovery and development of new medicines, Pfizer continually reviews its pipeline of potential new therapies. Following the closure of the Natureceuticals group within Pfizer, the company has determined that the development of P57 might be best achieved by another organization. As a consequence, Phytopharm is now free to license P57 to other parties. The company also stated that clinical data of P57 in patients encourage further study of the natural material as a therapy for obesity.